FundedIQ
Biotechnology

BrainEver: Funding, Investors & Team (Sep 2026)

BrainEver's new therapeutic approach is based on the research conducted by Alain Prochiantz and his team regarding brain development and function. They found that homeoproteins, originally thought to be involved only in early development, also play a crucial role in regulating neuronal functions throughout life. BrainEver believes that by administering homeoproteins to patients, it may be possible to enhance the physiological resilience of neurons and improve clinical symptoms. They are currently investigating different homeoproteins for various neurodegenerative diseases, with Engrailed 1 (BREN01) showing promise for Parkinson's Disease and ALS treatment. Additionally, BrainEver is working on developing drug candidates for Huntington's Disease and Optic Neuropathies.

www.brainever.com LinkedIn Saint-antoine, France 11-50 employees
Biopharma Biotechnology Life Science
Total raised
$38.9M
Rounds
1
Latest
Series B
Jul 2025

BrainEver has raised $38.9M across 1 funding round on record, the most recent a Series B of $38.9M announced in Jul 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

BrainEver Company Profile and Key Stats

Total funding raised
$38.9M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$38.9M in Jul 2025
Employees
11-50
reported band
Headquarters
Saint-antoine, France

Latest funding round on record: Jul 2025.

BrainEver Funding Rounds

Date
Round
Amount
Series B
$38.9M

BrainEver Founders and Leadership Team

Name
Role
Contact
Alain Prochiantz
Founder
Locked

Contact details for the BrainEver team: 1 of 1 has an email address on file.

Start 14-day free trial →

BrainEver Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,705
$6.7M
4,289
$30M

BrainEver's latest round of $38.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like BrainEver in Biotechnology and Saint-antoine

Companies Similar to BrainEver

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…

Series A $12.6M

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…

Series D $34.0M

NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…

Undisclosed round $6.9M

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…

Undisclosed round $1.7M

One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…

Undisclosed round

Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…

Undisclosed round $120M

NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…

Undisclosed round $8.4M

AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…

Undisclosed round $11.6M

Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…

Undisclosed round $116M

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…

Undisclosed round $7.0M

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…

Undisclosed round $45.0M

AB Science was established in 2001 by a group of individuals in the medical and business fields who are…

Undisclosed round $3.7M

BrainEver Funding FAQs

What does BrainEver do?

BrainEver's new therapeutic approach is based on the research conducted by Alain Prochiantz and his team regarding brain development and function. They found that homeoproteins, originally thought to be involved only in early development, also play a crucial role in regulating neuronal functions throughout life. BrainEver believes that by administering homeoproteins to patients, it may be possible to enhance the physiological resilience of neurons and improve clinical symptoms. They are currently investigating different homeoproteins for various neurodegenerative diseases, with Engrailed 1 (BREN01) showing promise for Parkinson's Disease and ALS treatment. Additionally, BrainEver is working on developing drug candidates for Huntington's Disease and Optic Neuropathies.

How much funding has BrainEver raised?

BrainEver has raised $38.9M across 1 round on record. The most recent is a Series B of $38.9M announced in Jul 2025.

When did BrainEver last raise funding?

BrainEver's most recent funding round on record is a Series B of $38.9M, announced in Jul 2025.

Who founded BrainEver?

FundedIQ lists Alain Prochiantz (Founder) at BrainEver.

Where is BrainEver headquartered?

BrainEver is based in Saint-antoine, Rhone-Alpes, France.

How many employees does BrainEver have?

BrainEver is in the 11-50 employee band.

How does BrainEver's funding compare to other Biotechnology startups?

BrainEver's latest round of $38.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's BrainEver Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BrainEver is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.